PATENT CLAIM ANALYSIS

Application Number: 15770569
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["424", "468000"]

Abstract:
The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.

Claim (Index 1):
An oral enteric high-dose tablet comprising as an active substance 1000 mg of mesalazine or a pharmaceutically acceptable salt thereof and at least one excipient not containing matrix-forming substances, wherein the mass of the high-dose tablet is at most 35% higher than the mass of the active substance and the at least one excipient consists of polyvinyl pyrrolidone, wherein the high-dose tablet has at least one film coating comprising an enteric polymer and making up less than 10% by weight based on the total weight of the high-dose tablet.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 91.0
- Lexical Diversity: 1.1
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13790809', '15536334', '13951951', '10360410', '12236157']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6782530545063712
- 35 USC 102 Novelty (BERT): 0.4915105107703271
- Combined Prediction Score: 0.6595788001327667
- Mean Citation Score: 198.664118
- Max Citation Score: 203.6724
- Similarity Product: 139.48264701125623

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test